tradipitant (VLY-686) / Vanda 
Welcome,         Profile    Billing    Logout  
 2 Diseases   5 Trials   5 Trials   115 News 


«12
  • ||||||||||  tradipitant (VLY-686) / Vanda
    Clinical:  Tradipitant in the Treatment of Motion Sickness: A Randomized, Double-Blind, Placebo-Controlled Study. (Pubmed Central) -  Nov 1, 2020   
    Across these trips, motion sickness symptoms were significantly lower in the tradipitant group compared to the placebo group (tradipitant = 3.19, placebo = 4.57, p = 0.0235). Tradipitant has the potential to be an effective therapy for the prevention of vomiting and treatment of nausea in people with motion sickness.
  • ||||||||||  tradipitant (VLY-686) / Vanda
    Trial completion:  Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE) (clinicaltrials.gov) -  Apr 27, 2020   
    P3,  N=375, Completed, 
    Tradipitant has the potential to be an effective therapy for the prevention of vomiting and treatment of nausea in people with motion sickness. Recruiting --> Completed
  • ||||||||||  tradipitant (VLY-686) / Vanda
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness (clinicaltrials.gov) -  Mar 11, 2020   
    P2,  N=150, Completed, 
    Not yet recruiting --> Enrolling by invitation Recruiting --> Completed | N=250 --> 150 | Trial completion date: Mar 2019 --> Jun 2019 | Trial primary completion date: Mar 2019 --> Jun 2019
  • ||||||||||  tradipitant (VLY-686) / Vanda
    WHOLE GENOME SEQUENCING ANALYSIS OF GASTROPARESIS () -  Jan 28, 2020 - Abstract #DDW2020DDW_2496;    
    We investigated the frequency and effect of rare loss-of-function (LOF) variants in patients with idiopathic and diabetic gastroparesis enrolled in a clinical study, VLY686-2301...Whole-genome sequencing of gastroparesis patient samples showed enrichment for rare variants in the MTLR in cases compared with controls. The identified LOF variants within the region can serve as a risk factor for disease as well as inform treatments, especially given the knowledge of different responses to treatment
  • ||||||||||  tradipitant (VLY-686) / Vanda
    WHOLE GENOME SEQUENCING ANALYSIS OF GASTROPARESIS IDENTIFIES NOVEL RISK LOCI (E-Poster Terminal 3) -  Aug 18, 2019 - Abstract #UEGW2019UEGW_3814;    
    Whole genome sequencing of gastroparesis patient samples showed enrichment for rare variants in the MTLR in cases compared with controls. The identified LOF variants within the region can serve as risk factor for disease as well as inform treatments, especially given the knowledge of different response to treatment.
  • ||||||||||  tradipitant (VLY-686) / Vanda
    WHOLE GENOME SEQUENCING ANALYSIS OF GASTROPARESIS IDENTIFIES NOVEL RISK LOCI (Poster Exhibition - Hall 7) -  Aug 18, 2019 - Abstract #UEGW2019UEGW_1793;    
    Whole genome sequencing of gastroparesis patient samples showed enrichment for rare variants in the MTLR in cases compared with controls. The identified LOF variants within the region can serve as risk factor for disease as well as inform treatments, especially given the knowledge of different response to treatment.
  • ||||||||||  tradipitant (VLY-686) / Vanda
    Tradipitant Complete Responder Analysis in Gastroparesis Patients (Exhibit Halls 3 and 4 (Street Level)) -  Aug 8, 2019 - Abstract #ACG2019ACG_3121;    
    Subjects receiving tradipitant had a significant decrease in their average nausea score compared to placebo with LS mean difference (95% CI) of -0.53 (-0.92, -0.13, p=0.0099) as well as a significant increase in nausea free days (28.8% increase on tradipitant compared to 15.0% increase on placebo, p=0.0160). A complete nausea response as defined by a nausea severity score ≤ 1 at week 4 was found to occur in 33% of patients on tradipitant compared to 12% of patients on placebo (p=0.0013).
  • ||||||||||  tradipitant (VLY-686) / Vanda
    Whole Genome Sequencing Analysis of Gastroparesis (Exhibit Halls 3 and 4 (Street Level)) -  Aug 8, 2019 - Abstract #ACG2019ACG_1713;    
    Motilin is a 22 amino acid peptide hormone expressed throughout the gastrointestinal (GI) tract. The protein encoded by this gene is a motilin receptor which is a member of the G-protein coupled receptor 1 family.
  • ||||||||||  orvepitant (GW 823296) / NeRRe, tradipitant (VLY-686) / Vanda, serlopitant (JTS 661) / Menlo Therap
    Review, Journal:  NK-1 Receptor Antagonists and Pruritus: Review of Current Literature. (Pubmed Central) -  Jun 14, 2019   
    For this purpose, a systemic electronic literature search of the PubMed and CINAHL databases, Cochrane Library, and clinicaltrials.gov website was performed. Based on currently available data, it can be concluded that NK-1 inhibitors show significant antipruritic potential for treatment of chronic pruritus in different dermatological conditions, but further studies are needed to establish the best indications and dosage of these drugs.
  • ||||||||||  tradipitant (VLY-686) / Vanda
    Trial completion date, Trial primary completion date:  VP-VLY-686-2301: Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis (clinicaltrials.gov) -  Apr 27, 2018   
    P2,  N=150, Recruiting, 
    Based on currently available data, it can be concluded that NK-1 inhibitors show significant antipruritic potential for treatment of chronic pruritus in different dermatological conditions, but further studies are needed to establish the best indications and dosage of these drugs. Trial completion date: Nov 2017 --> Dec 2018 | Trial primary completion date: Oct 2017 --> Dec 2018